Enterobiotix
Clinical-stage microbiome therapeutics developing the oral drug EBX-102-02 for irritable bowel syndrome and related gut and liver diseases
Highlights
- New on EvolcAdded 2026-10-28
About Enterobiotix
EnteroBiotix develops EBX-102-02, an orally administered, high-diversity microbiome therapeutic in clinical development for irritable bowel syndrome (IBS) and other diseases linked to the gastrointestinal tract and the liver. The powder is made with the company's proprietary AMPLA drying technology, is designed to be refrigerator-stable, and is protected by granted composition of matter patents. EBX-102-02 is investigational.
The company targets patients with gastrointestinal disease and is seeking licensing partners to advance late-stage clinical development and commercialisation of EBX-102-02. Its platform includes the Number2 donor programme for donor screening and management and MHRA-licensed GMP manufacturing facilities.
EnteroBiotix was founded in 2017 and is headquartered in Bellshill, Scotland. The company reports a £19m raise to fund a Phase 2b trial in IBS, and the first patient has been dosed in the RISE Phase 2b study of EBX-102-02 in IBS with constipation.
Product: EBX-102-02, an oral full-spectrum microbiome therapeutic in clinical development for irritable bowel syndrome.
Jobs at Enterobiotix
Leadership
- James McIlroy · CEO & BOARD MEMBERSource: company website
- James Barnes · COOSource: company website
- Melissa Strange · CFOSource: company website
More biotech & pharma companies
Enterprise Therapeutics
Develops investigational medicines for people with cystic fibrosis and other respiratory diseasesNew on EvolcEpidarex Exeed
Seeds early-stage life science ventures by developing breakthrough therapeutic research into investable assetsNew on EvolcEpitopea
Develops off-the-shelf RNA cancer immunotherapies for patients with difficult-to-treat cancersNew on EvolcEpsilogen
Develops antibody-based cancer treatments, including a clinical candidate for ovarian cancerNew on EvolcExtracellular
CDMO for cell-based food, cosmetics and materials products, offering bioprocess development and up to 2,000L manufacturingNew on EvolcSalary transparentExymes
Enzyme-based DNA/RNA extraction reagents and kits for forensic, academic, veterinary and environmental labsYoung companyNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Squarespace